Jeff Yass’s Petros Pharmaceuticals PTPI Stock Holding History

Jeff Yass’s Portfolio PTPI Stock Details PTPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-114	Closed	-$15K	–	13415
2022 Q3	$15K	Buy	+114	New	+$20.7K	﹤0.01%	12700
2022 Q2	–	Sell	-211	Closed	-$82K	–	13729
2022 Q1	$82K	Buy	211 +55	+35%	+$23.2K	﹤0.01%	12036
2021 Q4	$130K	Buy	+156	New	+$91.4K	﹤0.01%	11953

Other funds holding PTPI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Jeff Yass's PTPI Position: Q4 2022 in Review

Jeff Yass sold out of Petros Pharmaceuticals (PTPI) in Q4 2022, closing a stake of 72 shares — an estimated $9K sold.

Jeff Yass first reported a position in PTPI in Q4 2021 and held it in 3 quarters. The position peaked at $225K in Q4 2021. 7 funds tracked by Wall St. Rank hold PTPI as of Q4 2022.

Jeff Yass reported no remaining Petros Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Jeff Yass sold 72 Petros Pharmaceuticals shares in Q4 2022, an estimated $9K.
Jeff Yass first reported a position in Petros Pharmaceuticals in Q4 2021 and held it in 3 quarters.
Jeff Yass's Petros Pharmaceuticals position peaked at $225K in Q4 2021.
7 funds tracked by Wall St. Rank held Petros Pharmaceuticals as of Q4 2022.

Based on Susquehanna International Group's 13F filing for Q4 2022, filed 14 Feb 2023.